BACKGROUND: GD2 and GD3 are the tumor-associated glycolipid antigens found in a broad spectrum of human cancers. GD2-specific antibody is currently a standard of care for high-risk neuroblastoma therapy. In this study, the pattern of GD2 and GD3 expression among pediatric/adolescent or young adult tumors was determined, providing companion diagnostics for targeted therapy. METHODS: Ninety-two specimens of human osteosarcoma (OS), rhabdomyosarcoma (RMS), Ewing family of tumors, desmoplastic small round cell tumor (DSRCT), and melanoma were analyzed for GD2/GD3 expression by immunohistochemistry. Murine monoclonal antibody 3F8 was used for GD2 staining, and R24 for GD3. Staining was scored according to both intensity and percentage of positive tumor cells from 0 to 4. RESULTS: Both gangliosides were highly prevalent in OS and melanoma. Among other tumors, GD3 expression was higher than GD2 expression. Most OS samples demonstrated strong staining for GD2 and GD3, whereas expression for other tumors was highly variable. Mean intensity of GD2 expression was significantly more heterogeneous (P < 0.001) when compared to GD3 across tumor types. When assessing the difference between GD2 and GD3 expression in all tumor types combined, GD3 expression had a significantly higher score (P = 0.049). When analyzed within each cancer, GD3 expression was significantly higher only in DSRCT (P = 0.002). There was no statistical difference in either GD2 or GD3 expression between primary and recurrent sarcomas. CONCLUSION: GD2/GD3 expression among pediatric solid tumors is common, albeit with variable level of expression. Especially for patients with sarcoma, these gangliosides can be potential targets for antibody-based therapies.
BACKGROUND:GD2 and GD3 are the tumor-associated glycolipid antigens found in a broad spectrum of humancancers. GD2-specific antibody is currently a standard of care for high-risk neuroblastoma therapy. In this study, the pattern of GD2 and GD3 expression among pediatric/adolescent or young adult tumors was determined, providing companion diagnostics for targeted therapy. METHODS: Ninety-two specimens of humanosteosarcoma (OS), rhabdomyosarcoma (RMS), Ewing family of tumors, desmoplastic small round cell tumor (DSRCT), and melanoma were analyzed for GD2/GD3 expression by immunohistochemistry. Murine monoclonal antibody 3F8 was used for GD2 staining, and R24 for GD3. Staining was scored according to both intensity and percentage of positive tumor cells from 0 to 4. RESULTS: Both gangliosides were highly prevalent in OS and melanoma. Among other tumors, GD3 expression was higher than GD2 expression. Most OS samples demonstrated strong staining for GD2 and GD3, whereas expression for other tumors was highly variable. Mean intensity of GD2 expression was significantly more heterogeneous (P < 0.001) when compared to GD3 across tumor types. When assessing the difference between GD2 and GD3 expression in all tumor types combined, GD3 expression had a significantly higher score (P = 0.049). When analyzed within each cancer, GD3 expression was significantly higher only in DSRCT (P = 0.002). There was no statistical difference in either GD2 or GD3 expression between primary and recurrent sarcomas. CONCLUSION:GD2/GD3 expression among pediatric solid tumors is common, albeit with variable level of expression. Especially for patients with sarcoma, these gangliosides can be potential targets for antibody-based therapies.
Authors: Jaume Mora; Shakeel Modak; Nai-Kong Cheung; Paul Meyers; Enrique de Alava; Brian Kushner; Heather Magnan; Oscar M Tirado; Michael Laquaglia; Marc Ladanyi; Juan Rosai Journal: Future Oncol Date: 2015 Impact factor: 3.404
Authors: Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana Journal: J Clin Oncol Date: 2014-04-07 Impact factor: 44.544
Authors: Yuh-Jin Liang; Yao Ding; Steven B Levery; Marlin Lobaton; Kazuko Handa; Sen-itiroh Hakomori Journal: Proc Natl Acad Sci U S A Date: 2013-03-11 Impact factor: 11.205
Authors: Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Vincent I Poon; Michael Roth; Sajida Piperdi; David Geller; Jonathan Gill; Erin R Rudzinski; Douglas S Hawkins; Richard Gorlick Journal: Clin Sarcoma Res Date: 2015-01-24
Authors: Sarah A Richman; Selene Nunez-Cruz; Babak Moghimi; Lucy Z Li; Zachary T Gershenson; Zissimos Mourelatos; David M Barrett; Stephan A Grupp; Michael C Milone Journal: Cancer Immunol Res Date: 2017-11-27 Impact factor: 11.151
Authors: Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder Journal: Cancer Res Date: 2019-04-23 Impact factor: 12.701
Authors: Carles Monterrubio; Sonia Paco; Nagore G Olaciregui; Guillem Pascual-Pasto; Monica Vila-Ubach; Maria Cuadrado-Vilanova; M Mar Ferrandiz; Helena Castillo-Ecija; Romina Glisoni; Nataliya Kuplennik; Achim Jungbluth; Carmen de Torres; Cinzia Lavarino; N K V Cheung; Jaume Mora; Alejandro Sosnik; Angel M Carcaboso Journal: J Control Release Date: 2017-04-12 Impact factor: 9.776
Authors: Etienne C Gozlan; Boris I Chobrutskiy; Saif Zaman; Michelle Yeagley; George Blanck Journal: J Mol Neurosci Date: 2021-03-05 Impact factor: 3.444
Authors: Irene Y Cheung; Nai-Kong V Cheung; Shakeel Modak; Audrey Mauguen; Yi Feng; Ellen Basu; Stephen S Roberts; Govind Ragupathi; Brian H Kushner Journal: J Clin Oncol Date: 2020-12-16 Impact factor: 44.544